<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Tivic Health Systems Inc — News on 6ix</title>
<link>https://6ix.com/company/tivic-health-systems-inc</link>
<description>Latest news and press releases for Tivic Health Systems Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 23 Apr 2026 20:05:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/tivic-health-systems-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835c9fd78dffbe2df11c890.webp</url>
<title>Tivic Health Systems Inc</title>
<link>https://6ix.com/company/tivic-health-systems-inc</link>
</image>
<item>
<title>Tivic Health Systems Rebrands as Valion Bio, Reflecting Completed Transformation into a Late-Stage Biopharmaceutical Company with Government-Backed Asset and Potential Multiple Revenue Stream Model</title>
<link>https://6ix.com/company/tivic-health-systems-inc/news/tivic-health-systems-rebrands-as-valion-bio-reflecting-completed-transformation-into-a-late-stage-biopharmaceutical-company-with-government-backed-asset-and-potential-multiple-revenue-stream-model</link>
<guid isPermaLink="true">https://6ix.com/company/tivic-health-systems-inc/news/tivic-health-systems-rebrands-as-valion-bio-reflecting-completed-transformation-into-a-late-stage-biopharmaceutical-company-with-government-backed-asset-and-potential-multiple-revenue-stream-model</guid>
<pubDate>Thu, 23 Apr 2026 20:05:00 GMT</pubDate>
<description>Tivic Health Systems, Inc. (Nasdaq: TIVC) today announced it is changing its corporate name to Valion Bio, Inc. and its Nasdaq ticker symbol from TIVC to VBIO, effective at market open on Tuesday, April 28, 2026. The CUSIP number for the company's common stock will remain unchanged.</description>
</item>
<item>
<title>Tivic Health Selected to Present Entolimod™ as a Radiation Countermeasure and its Plans for an Oral Transmucosal Program to the Department of War Tech Watch Program on May 7th</title>
<link>https://6ix.com/company/tivic-health-systems-inc/news/tivic-health-selected-to-present-entolimodtm-as-a-radiation-countermeasure-and-its-plans-for-an-oral-transmucosal-program-to-the-department-of-war-tech-watch-program-on-may-7th</link>
<guid isPermaLink="true">https://6ix.com/company/tivic-health-systems-inc/news/tivic-health-selected-to-present-entolimodtm-as-a-radiation-countermeasure-and-its-plans-for-an-oral-transmucosal-program-to-the-department-of-war-tech-watch-program-on-may-7th</guid>
<pubDate>Wed, 15 Apr 2026 04:00:00 GMT</pubDate>
<description>SAN ANTONIO, April 15, 2026 /PRNewswire/ -- Tivic Health Systems, Inc. (Nasdaq: TIVC), a clinical-stage immunotherapeutics company, today announced it has</description>
</item>
<item>
<title>Tivic Receives Formal Request for Information from Ukrainian Ministry of Health Regarding Strategic Stockpiling of Entolimod</title>
<link>https://6ix.com/company/tivic-health-systems-inc/news/tivic-receives-formal-request-for-information-from-ukrainian-ministry-of-health-regarding-strategic-stockpiling-of-entolimod</link>
<guid isPermaLink="true">https://6ix.com/company/tivic-health-systems-inc/news/tivic-receives-formal-request-for-information-from-ukrainian-ministry-of-health-regarding-strategic-stockpiling-of-entolimod</guid>
<pubDate>Tue, 31 Mar 2026 04:00:00 GMT</pubDate>
<description>SAN ANTONIO, TX / ACCESS Newswire / March 31, 2026 / Tivic Health Systems, Inc. (Nasdaq:TIVC), a clinical-stage immunotherapeutics company, today announced it</description>
</item>
<item>
<title>Tivic Secures NIAID Non-Clinical Evaluation Agreement for Entolimod, Targeting Gastrointestinal Acute Radiation Syndrome</title>
<link>https://6ix.com/company/tivic-health-systems-inc/news/tivic-secures-niaid-non-clinical-evaluation-agreement-for-entolimod-targeting-gastrointestinal-acute-radiation-syndrome</link>
<guid isPermaLink="true">https://6ix.com/company/tivic-health-systems-inc/news/tivic-secures-niaid-non-clinical-evaluation-agreement-for-entolimod-targeting-gastrointestinal-acute-radiation-syndrome</guid>
<pubDate>Thu, 26 Mar 2026 04:00:00 GMT</pubDate>
<description>Armed Forces Radiobiology Research Institute (AFRRI) Will Conduct the Gastrointestinal Acute Radiation Syndrome (GI-ARS) Study SAN ANTONIO, TX / ACCESS</description>
</item>
<item>
<title>Tivic Reports Full Year 2025 Results</title>
<link>https://6ix.com/company/tivic-health-systems-inc/news/tivic-reports-full-year-2025-results</link>
<guid isPermaLink="true">https://6ix.com/company/tivic-health-systems-inc/news/tivic-reports-full-year-2025-results</guid>
<pubDate>Wed, 25 Mar 2026 04:00:00 GMT</pubDate>
<description>Completes Strategic Transformation into an Immunotherapy Company and Continues to Advance Entolimod Platform Toward Potential Funding PartnershipsConference</description>
</item>
<item>
<title>Tivic To Report 2025 Year-End Financial Results Via Conference Call and Webcast on March 25th at 1:30pm PT / 4:30pm ET</title>
<link>https://6ix.com/company/tivic-health-systems-inc/news/tivic-to-report-2025-year-end-financial-results-via-conference-call-and-webcast-on-march-25th-at-130pm-pt-430pm-et</link>
<guid isPermaLink="true">https://6ix.com/company/tivic-health-systems-inc/news/tivic-to-report-2025-year-end-financial-results-via-conference-call-and-webcast-on-march-25th-at-130pm-pt-430pm-et</guid>
<pubDate>Fri, 20 Mar 2026 04:00:00 GMT</pubDate>
<description>SAN ANTONIO, TX / ACCESS Newswire / March 20, 2026 / Tivic Health Systems, Inc. (Nasdaq:TIVC), a late-stage immunotherapeutics company, today announced that</description>
</item>
<item>
<title>Biotech Veteran Michael K. Handley Named CEO of Tivic Health Systems to Spearhead Strategic Expansion in Biopharma</title>
<link>https://6ix.com/company/tivic-health-systems-inc/news/biotech-veteran-michael-k-handley-named-ceo-of-tivic-health-systems-to-spearhead-strategic-expansion-in-biopharma</link>
<guid isPermaLink="true">https://6ix.com/company/tivic-health-systems-inc/news/biotech-veteran-michael-k-handley-named-ceo-of-tivic-health-systems-to-spearhead-strategic-expansion-in-biopharma</guid>
<pubDate>Wed, 04 Mar 2026 13:30:00 GMT</pubDate>
<description>SAN FRANCISCO, CA / ACCESS Newswire / March 4, 2026 / Tivic Health Systems, Inc. (Nasdaq:TIVC) ("Tivic" or the "Company"), a late-stage immunotherapeutics company, today announced that its Board of Directors has appointed Michael K. Handley as Chief ...</description>
</item>
<item>
<title>Tivic and BARDA Continue Discussions of Entolimod for Acute Radiation Syndrome on March 10</title>
<link>https://6ix.com/company/tivic-health-systems-inc/news/tivic-and-barda-continue-discussions-of-entolimod-for-acute-radiation-syndrome-on-march-10</link>
<guid isPermaLink="true">https://6ix.com/company/tivic-health-systems-inc/news/tivic-and-barda-continue-discussions-of-entolimod-for-acute-radiation-syndrome-on-march-10</guid>
<pubDate>Wed, 18 Feb 2026 14:15:00 GMT</pubDate>
<description>Initial presentation on January 26, 2026 showcased Entolimod's potential to mitigate and prevent both gastrointestinal and hematopoietic injury from ionizing radiation exposure. FREMONT, CA / ACCESS Newswire / February 18, 2026 / Tivic (Nasdaq:TIVC), ...</description>
</item>
<item>
<title>Tivic, BARDA Discuss Entolimod(TM) for Acute Radiation Syndrome at TechWatch Meeting</title>
<link>https://6ix.com/company/tivic-health-systems-inc/news/tivic-barda-discuss-entolimod-tm-133000710</link>
<guid isPermaLink="true">https://6ix.com/company/tivic-health-systems-inc/news/tivic-barda-discuss-entolimod-tm-133000710</guid>
<pubDate>Wed, 28 Jan 2026 13:30:00 GMT</pubDate>
<description>January 26 Presentation highlighted Entolimod's potential to mitigate and prevent both gastrointestinal and hematopoietic injury from ionizing radiation exposure BARDA has requested a follow-up meeting to continue the discussion on the potential utility ...</description>
</item>
<item>
<title>Tivic to Showcase Strategic Pivot and Forward Outlook on Advancing Entolimod(TM) to Commercialization at DealFlow Discovery Conference</title>
<link>https://6ix.com/company/tivic-health-systems-inc/news/tivic-showcase-strategic-pivot-forward-151000567</link>
<guid isPermaLink="true">https://6ix.com/company/tivic-health-systems-inc/news/tivic-showcase-strategic-pivot-forward-151000567</guid>
<pubDate>Mon, 26 Jan 2026 15:10:00 GMT</pubDate>
<description>CEO Presentation to Include Updates and Further Information on the Following Topics: Entolimod Cell Line Verification Success; 200x Manufacturing Scale-Up with Reproducible Quality; BARDA TechWatch Engagement; Creation of Velocity Bioworks, An Integrated ...</description>
</item>
<item>
<title>Tivic CEO To Present at the Upcoming Emerging Growth's January 2026 Virtual Conference</title>
<link>https://6ix.com/company/tivic-health-systems-inc/news/tivic-ceo-present-upcoming-emerging-225000030</link>
<guid isPermaLink="true">https://6ix.com/company/tivic-health-systems-inc/news/tivic-ceo-present-upcoming-emerging-225000030</guid>
<pubDate>Tue, 20 Jan 2026 22:50:00 GMT</pubDate>
<description>Presentation will Cover Recent Corporate Milestones Including Acceleration of Manufacturing Readiness for Entolimod™ FREMONT, CA / ACCESS Newswire / January 20, 2026 /Tivic Health® Systems, Inc. (NASDAQ:TIVC), a late-stage immunotherapeutics ...</description>
</item>
<item>
<title>Tivic Delivers 200x Scale-up in Manufacturing for Lead Drug Candidate Entolimod(TM) And Achieves Reproducible Yields, Potency and Purity</title>
<link>https://6ix.com/company/tivic-health-systems-inc/news/tivic-delivers-200x-scale-manufacturing-140000252</link>
<guid isPermaLink="true">https://6ix.com/company/tivic-health-systems-inc/news/tivic-delivers-200x-scale-manufacturing-140000252</guid>
<pubDate>Mon, 12 Jan 2026 14:00:00 GMT</pubDate>
<description>Company demonstrates commercial-scale production of its Toll-like Receptor 5 (TLR5) agonist for Acute Radiation Syndrome (ARS) and Neutropenia through wholly owned contract development manufacturing organization (CDMO), Velocity Bioworks Company's ...</description>
</item>
<item>
<title>Tivic Announces Special Webcast To Discuss Its Recent Acquisition of CDMO Assets - Highlighting Near-Term Strategic Potential and Immediate Contributions to Accelerated Drug Development Timelines</title>
<link>https://6ix.com/company/tivic-health-systems-inc/news/tivic-announces-special-webcast-discuss-133000737</link>
<guid isPermaLink="true">https://6ix.com/company/tivic-health-systems-inc/news/tivic-announces-special-webcast-discuss-133000737</guid>
<pubDate>Thu, 08 Jan 2026 13:30:00 GMT</pubDate>
<description>Conference Call to be Hosted on Monday, January 12 at 1:30 PM PT/4:30 PM ET FREMONT, CA / ACCESS Newswire / January 8, 2026 /Tivic Health® Systems, Inc. (Nasdaq:TIVC), a late-stage immunotherapeutics company, today announced that Management will host ...</description>
</item>
<item>
<title>Tivic Acquires Ready-to-Scale cGMP Manufacturing and Development Assets to Accelerate Commercialization of Entolimod; Tivic Growth Backed By $90M+ Financing Package</title>
<link>https://6ix.com/company/tivic-health-systems-inc/news/tivic-acquires-ready-scale-cgmp-144500363</link>
<guid isPermaLink="true">https://6ix.com/company/tivic-health-systems-inc/news/tivic-acquires-ready-scale-cgmp-144500363</guid>
<pubDate>Thu, 11 Dec 2025 14:45:00 GMT</pubDate>
<description>Acquisition creates additional near-term revenue opportunities from newly formed Contract Development and Manufacturing Organization (CDMO) subsidiary, Velocity Bioworks™ Financing led by 3i, LP includes $16M debt financing for the purchase ...</description>
</item>
<item>
<title>Tivic Secures BARDA Meeting for Entolimod(TM) for Acute Radiation Syndrome</title>
<link>https://6ix.com/company/tivic-health-systems-inc/news/tivic-secures-barda-meeting-entolimod-133000313</link>
<guid isPermaLink="true">https://6ix.com/company/tivic-health-systems-inc/news/tivic-secures-barda-meeting-entolimod-133000313</guid>
<pubDate>Tue, 18 Nov 2025 13:30:00 GMT</pubDate>
<description>Meeting with Radiological and Nuclear Medical Countermeasures Program FREMONT, CA / ACCESS Newswire / November 18, 2025 / Tivic Health® Systems, Inc. (NASDAQ:TIVC), a late-stage therapeutics company, today announced it has secured an exclusive Techwatch ...</description>
</item>
<item>
<title>Tivic Reports Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/tivic-health-systems-inc/news/tivic-reports-third-quarter-2025-213000556</link>
<guid isPermaLink="true">https://6ix.com/company/tivic-health-systems-inc/news/tivic-reports-third-quarter-2025-213000556</guid>
<pubDate>Fri, 14 Nov 2025 21:30:00 GMT</pubDate>
<description>Continues Execution of Strategic Transformation and Advancement of Biologics Pipeline FREMONT, CA / ACCESS Newswire / November 14, 2025 / Tivic Health® Systems, Inc. (Nasdaq:TIVC), a diversified immunotherapeutics company, today announced financial ...</description>
</item>
<item>
<title>Tivic Health Reports Findings of Clinical Optimization Trial of Non-Invasive Cervical Vagus Nerve Stimulation (ncVNS)</title>
<link>https://6ix.com/company/tivic-health-systems-inc/news/tivic-health-reports-findings-clinical-133000727</link>
<guid isPermaLink="true">https://6ix.com/company/tivic-health-systems-inc/news/tivic-health-reports-findings-clinical-133000727</guid>
<pubDate>Thu, 13 Nov 2025 13:30:00 GMT</pubDate>
<description>The study demonstrated that personalizing the stimulation parameters to each user dramatically enhanced autonomic effects FREMONT, CA / ACCESS Newswire / November 13, 2025 / Tivic Health Systems, Inc. (Nasdaq:TIVC), a diversified immunotherapeutics ...</description>
</item>
<item>
<title>Tivic Expands Intellectual Property Portfolio</title>
<link>https://6ix.com/company/tivic-health-systems-inc/news/tivic-expands-intellectual-property-portfolio-140000065</link>
<guid isPermaLink="true">https://6ix.com/company/tivic-health-systems-inc/news/tivic-expands-intellectual-property-portfolio-140000065</guid>
<pubDate>Mon, 10 Nov 2025 14:00:00 GMT</pubDate>
<description>FREMONT, Calif., November 10, 2025--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, today announced it is expanding its intellectual property portfolio with the recent filing of two additional patent applications with the United States Patent and Trademark Office.</description>
</item>
<item>
<title>Tivic Health to Report Third Quarter 2025 Financial Results on November 14th Via Conference Call and Webcast</title>
<link>https://6ix.com/company/tivic-health-systems-inc/news/tivic-health-report-third-quarter-143000719</link>
<guid isPermaLink="true">https://6ix.com/company/tivic-health-systems-inc/news/tivic-health-report-third-quarter-143000719</guid>
<pubDate>Thu, 06 Nov 2025 14:30:00 GMT</pubDate>
<description>FREMONT, Calif., November 06, 2025--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified immunotherapeutics company, today announced that it will report its third quarter results for 2025 via pre-recorded conference call and webcast on Friday, November 14, 2025 at 1:30 PM PT / 4:30 PM ET.</description>
</item>
<item>
<title>Tivic CEO, Jennifer Ernst, to Join Panel at 8th Annual Northwell Health Innovation Constellation Forum on Thursday, Oct. 23</title>
<link>https://6ix.com/company/tivic-health-systems-inc/news/tivic-ceo-jennifer-ernst-join-180000147</link>
<guid isPermaLink="true">https://6ix.com/company/tivic-health-systems-inc/news/tivic-ceo-jennifer-ernst-join-180000147</guid>
<pubDate>Wed, 22 Oct 2025 18:00:00 GMT</pubDate>
<description>FREMONT, Calif., October 22, 2025--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified immunotherapeutics company, today announced that CEO, Jennifer Ernst, will participate in the eighth annual Constellation Forum, a global conversation on Bioelectronic Medicine. She will join other leaders in the field to discuss the opportunities for advancing bioelectronic medicine.</description>
</item>
</channel>
</rss>